Navigation Links
VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch
Date:7/2/2008

SAN JOSE, Calif., July 2 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, announced today that it has asserted patent infringement claims in the United States District Court, Northern District of California, against biolitec Inc. (Biolitec), Dornier MedTech America, Inc. (Dornier) and NewStar Lasers, Inc. d/b/a CoolTouch, Inc. (CoolTouch).

Biolitec, CoolTouch and Dornier market endovenous laser ablation products for use in procedures which VNUS believes infringe several of its patents. VNUS is seeking an injunction prohibiting these companies from selling these products, in addition to monetary damages.

The new lawsuit involves patents that VNUS previously asserted in 2005 against Diomed Holdings, Inc., AngioDynamics, Inc. and Vascular Solutions, Inc. VNUS entered into an agreement on June 3, 2008 with AngioDynamics and Vascular Solutions that settled the 2005 lawsuit against those companies. As a part of the agreement, non-exclusive, non-sub-licensable patent licenses were granted to AngioDynamics and Vascular Solutions and the licensees stipulated that the VNUS patents-in-suit are valid, enforceable, and were infringed.

Brian Farley, President and CEO, commented, "The filing of this patent infringement suit is the next logical step in the enforcement of our intellectual property. We are committed to enforcement, while at the same time we remain open to discussing the potential opportunity for the defendant companies to obtain a limited license from VNUS."

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting 25 million Americans. The pioneering company in the field, VNUS now offers the ClosureFAST system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. VNUS devices have been used in more than 300,000 procedures worldwide. For more information, visit http://www.vnus.com/.

FORWARD-LOOKING STATEMENTS

VNUS has made forward-looking statements in this press release within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes", or variations of such words, are intended to identify such forward-looking statements in this press release. These statements are based on information available to VNUS as of the date of this press release and represent VNUS' judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors, including, among other things, the uncertain outcome of patent litigation and the responses by others to a settlement agreement. Therefore, the reader is cautioned not to rely on these forward-looking statements. VNUS expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. July 28, 2008: Status of Unlawfully Expelled Ahmadi Medical Students in Pakistan Still Unclear
2. ATS Medical to Participate at the Fourth Annual Collins Stewart Growth Conference
3. Breastfeeding.com Launches First Ever Social Network for Birth-Related Medical Professionals
4. New MagnaBloc™ Product Available from Gradient Medical
5. Grubb & Ellis Healthcare REIT Acquires Decatur Medical Plaza in Decatur, Ga.
6. Dr. Howard Epstein Joins Blue Cross as Medical Director for Commercial Operations and Clinical Design
7. Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis
8. Medical check-ups for intestinal cancer are hardly used
9. Southern Home Medical Equipment Announces June 2008 Revenues
10. Medical Tactile, Inc. Announces Appointment of Denis A. OConnor as CEO & Member of Board of Directors
11. National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... now offering treatments for patients with sleep apnea and TMJ disorders. These conditions ... and physical health. Dr. Rassouli provides personalized care to reduce the risk of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD ... Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical ... addition, technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: